Skip to main content
. 2022 Sep 24;22:18–33. doi: 10.1016/j.bioactmat.2022.09.015

Fig. 7.

Fig. 7

Evaluation of the ITGA5 antagonist AV3 in vivo. A) Immunohistochemical staining for CD31 (red) and nuclei (blue) in Panc-1/PSC and MiaPaca-2/PSC tumors treated with either vehicle or AV3. Scale bar = 100 μm. B) Quantification of the average lumen size based on CD31 staining including tumors from Panc-1/PSC and MiaPaCa-2/PSC (combined data, n = 4/cell type model, n = 8 total). Outliers have been identified using Z-score statistical analysis and have not been included in statistical analysis (Fig. S11, Supporting Information). C) Theoretical relative pressure at the inlet of compressed vessels in Panc-1/PSC and MiaPaCa-2/PSC tumors in mice based on previously established CFD simulations of different compression levels, based on n = 8 animals. D) Theoretical relative flow velocity in compressed vessels in Panc-1/PSC and MiaPaCa-2/PSC tumors in mice based on previously established CFD simulations of different compression levels, based on n = 8 animals. E) Accumulation of ICG dye in Panc-1/PSC and MiaPaCa-2/PSC tumors in mice treated with either vehicle or AV3. Isolated tumors were imaged using near-infrared animal imager, combined data, n = 4/cell type model, n = 8 total. Mean + SEM, **p < 0.01, ***p < 0.001.